Patients on prolonged orforglipron therapy should have periodic DEXA scans monitoring both body composition and bone density

If pancreatitis is suspected, Wegovy should be discontinued and appropriate diagnostic tests performed urgently Gallbladder problems : Rapid weight loss increases risk of gallstone formation, with cholelithiasis reported in approximately 1.6% of Wegovy users Intestinal obstruction/ileus : Cases have been reported in post-marketing surveillance, particularly in patients with pre-existing GI conditions Management strategies recommended by healthcare professionals include: Eating smaller, more frequent meals rather than large portions Avoiding high-fat, spicy, or heavily processed foods Staying well-hydrated, particularly if experiencing diarrhoea or vomiting, to prevent dehydration and potential acute kidney injury Not lying down immediately after eating to minimise reflux Ensuring adequate fibre intake to prevent constipation Taking the medication on the same day each week to maintain steady levels Most GI side effects improve over time as the body adjusts to the medication, typically becoming less troublesome after 4-8 weeks at each dose level

FotakisCMegariotisGChristodouleasDKritsiEZoumpoulakisPNtountaniotisDet alComparative study of the AT1 receptor prodrug antagonist candesartan cilexetil with other sartans on the interactions with membrane bilayers
Hair Loss Associated with Ozempic
In the US, several of these peptides sit on the FDAs Category 2 bulk-substance list as of this writing, and WADA banned BPC-157 for athletes in 2022